세계의 고형암 치료 시장 보고서(2025년)
Solid Tumor Cancer Treatment Global Market Report 2025
상품코드 : 1821701
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

고형암 치료 시장 규모는 향후 수년간 급성장할 것으로 예측 기간 동안의 성장은 맞춤형 의약품 트렌드, 면역요법 발전, 전 세계 보건 과제 및 신종 질병, 규제 프레임워크 및 의약품 승인, 의료 재정 및 환급 모델 변화 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 면역요법 발전, 정밀의학 및 바이오마커 식별, 병용요법, 디지털 헬스 통합, 치료 방식의 기술 혁신 등이 포함됩니다.

향후 5년간 13.5% 성장이라는 예측치는 이전 전망 대비 0.2% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 관세 인상으로 중국과 한국에서 원산지된 향후 CAR-T 세포 치료제 및 종양 절제술의 비용이 상승하여 미국 환자들의 부담이 가중될 전망입니다. 이는 환자 본인 부담금 증가와 생명 구제적 치료 지연으로 이어질 수 있습니다. 또한 상호 보복 관세와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 파급 효과는 더욱 광범위해질 것입니다.

향후 몇 년간 암 발병률 증가가 고형암 치료 시장을 상당한 수준으로 촉진할 것으로 예상됩니다. 암은 신체 세포의 급속하고 통제되지 않은 증식으로 비정상적 종양을 유발하는 중증 질환입니다. 고형암 치료란 암 환자의 신체에서 고형 종양을 제거하기 위한 치료법을 의미합니다. 예를 들어, 스위스에 본부를 두는 국제적인 공중위생기관인 세계보건기구(WHO)의 보고서에 따르면 2022년에 새롭게 2,000만명 가까이의 암 환자가 보고되어, 이 질병에 의한 사망자는 약 1,000만명에 이른다고 합니다. 인구통계학적 예측에 따르면 2050년에 암의 연간 이환수가 3,500만 명에 달할 수 있으며, 이는 2022년 수준에서 77% 증가했습니다. 폐암은 가장 많이 진단되는 암으로, 약 250만명의 신규 증례, 즉 세계 암 8명 중 1명을 차지하며, 이는 세계 전암의 12.4%를 차지합니다. 따라서 암 발생률 증가는 고형암 치료 시장 성장을 촉진하는 핵심 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Solid tumor cancer treatment pertains to addressing abnormal tissue masses that typically lack cysts or liquid regions. These tumors encompass various organs such as the brain, ovary, breast, colon, and others. The proliferation of tumor cells is primarily driven by cancer stem cells undergoing division.

The principal treatments for solid tumor cancer encompass chemotherapy, targeted therapy, immunotherapy, hormone therapy, and surgical interventions. Chemotherapy involves drug-based therapies aimed at halting cell division or eliminating cancer cells to impede their growth. Its applications extend across various cancer types such as breast, cervical, colorectal, lung, prostate, among others. These treatments are utilized across diverse end-users such as hospitals, research institutes, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The solid tumor cancer treatment market research report is one of a series of new reports from The Business Research Company that provides solid tumor cancer treatment market statistics, including solid tumor cancer treatment industry global market size, regional shares, competitors with a solid tumor cancer treatment market share, detailed solid tumor cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the solid tumor cancer treatment industry. This solid tumor cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The solid tumor cancer treatment market size has grown rapidly in recent years. It will grow from $232.2 billion in 2024 to $265.41 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to advancements in research and development, drug development and approvals, increased cancer incidence rates, growing aging population, patient advocacy and awareness.

The solid tumor cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $440.67 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to personalized medicine trends, immunotherapy advancements, global health challenges and emerging diseases, regulatory frameworks and drug approvals, shifts in healthcare financing and reimbursement models. Major trends in the forecast period include immunotherapy advancements, precision medicine and biomarker identification, combination therapies, digital health integration, technological innovations in treatment modalities.

The forecast of 13.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of next-gen CAR-T cell therapies and tumor ablation devices sourced from China and South Korea, exacerbating out-of-pocket expenses and delaying life-saving interventions. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer is expected to significantly drive the growth of the solid tumor cancer treatment market in the coming years. Cancer is a serious condition characterized by the rapid and uncontrolled reproduction of the body's cells, leading to abnormal growths. Solid tumor cancer treatment refers to therapies aimed at removing solid tumors from the bodies of cancer patients. For example, a report from the World Health Organization, a Switzerland-based international public health agency, indicated that in 2022, nearly 20 million new cancer cases were reported, resulting in approximately 10 million deaths from the disease. Demographic projections suggest that the annual incidence of cancer could reach 35 million by 2050, representing a 77% increase from 2022 levels. Lung cancer was the most frequently diagnosed type, accounting for around 2.5 million new cases, or one in every eight cancers globally, which constitutes 12.4% of all cancers worldwide. Thus, the increasing incidence of cancer is a key factor driving the growth of the solid tumor cancer treatment market.

The growing population is projected to drive the expansion of the solid tumor cancer treatment market in the coming years. An aging population refers to a demographic shift characterized by an increasing proportion of elderly individuals within a society over time. Solid tumor cancer treatment is specifically designed to address the unique challenges and complexities faced by older adults diagnosed with various types of solid tumors. For example, a report from the Population Reference Bureau, a Kenya-based nonprofit organization, noted that the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, the share of this age group within the overall population is projected to grow from 17% to 23% during the same timeframe. Therefore, the increasing aging population is a significant factor driving the growth of the solid tumor cancer treatment market.

Innovation in products and treatments has emerged as a notable trend in the solid tumor cancer treatment market, with major companies actively focusing on introducing new solutions to sustain their market positions. An illustrative example is Shanghai Henlius Biotech, a China-based biopharmaceutical company, which launched the PD-1 inhibitor HANSIZHUANG in March 2022. HANSIZHUANG, the company's first innovative monoclonal antibody, was developed for treating adults with advanced, unresectable, or metastatic MSI-H (microsatellite instability-high) solid tumors unresponsive to prior conventional treatments. This product innovation not only provides fresh hope for patients with MSI-H solid tumors but also aligns with the demand for precision immunotherapy, fostering the high-quality development of China's biopharmaceutical industry in the solid tumor cancer treatment market.

Prominent companies in the solid tumor cancer treatment market are directing their focus towards the development of monitoring platforms that leverage tailored tests, including personalized assays, for precise detection. Personalized assays involve customized laboratory tests or analytical procedures designed to examine specific characteristics or markers unique to an individual, often based on their genetic or molecular profile. An exemplary illustration is Invitae, a US-based medical genetics company, which, in collaboration with the Tracerx consortium at University College London, launched a personalized cancer monitoring platform in March 2022. This platform is specifically designed for the detection of minimal or molecular residual disease in patients with solid tumors. Utilizing personalized assays based on the patient's tumor, the platform identifies circulating tumor DNA (ctDNA) in the blood. These assays play a crucial role in helping clinicians assess patient risk, gauge treatment response, and predict the likelihood of recurrence.

In February 2024, AbbVie Inc., a U.S.-based pharmaceutical company, acquired ImmunoGen, Inc. This acquisition is part of AbbVie's strategy to bolster its oncology capabilities by specifically targeting unmet needs in cancer treatments. The company aims to enhance its solid tumor portfolio and expand its footprint in the oncology market. ImmunoGen, Inc. is a U.S.-based biotechnology firm specializing in the development of antibody-drug conjugate (ADC) therapeutics for cancer treatment.

Major companies operating in the solid tumor cancer treatment market include AstraZeneca plc, Amgen Inc., Bristol Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Olympus Medical Systems, Astellas Pharma Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Celldex Therapeutics Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eisai Co. Ltd., Exelixis Inc., Genentech Inc., Gilead Sciences Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., Karyopharm Therapeutics Inc., Kyowa Kirin Co. Ltd., MorphoSys AG, Regeneron Pharmaceuticals Inc., Sanofi SA, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Verastem Inc., Zymeworks Inc.

North America was the largest region in the solid tumor cancer treatment market in 2024. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the solid tumor cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The solid tumor cancer treatment market includes revenues earned by entities by treat solid tumor cancer through hormonal therapy, targeted drugs, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Solid Tumor Cancer Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on solid tumor cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for solid tumor cancer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The solid tumor cancer treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Solid Tumor Cancer Treatment Market Characteristics

3. Solid Tumor Cancer Treatment Market Trends And Strategies

4. Solid Tumor Cancer Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Solid Tumor Cancer Treatment Growth Analysis And Strategic Analysis Framework

6. Solid Tumor Cancer Treatment Market Segmentation

7. Solid Tumor Cancer Treatment Market Regional And Country Analysis

8. Asia-Pacific Solid Tumor Cancer Treatment Market

9. China Solid Tumor Cancer Treatment Market

10. India Solid Tumor Cancer Treatment Market

11. Japan Solid Tumor Cancer Treatment Market

12. Australia Solid Tumor Cancer Treatment Market

13. Indonesia Solid Tumor Cancer Treatment Market

14. South Korea Solid Tumor Cancer Treatment Market

15. Western Europe Solid Tumor Cancer Treatment Market

16. UK Solid Tumor Cancer Treatment Market

17. Germany Solid Tumor Cancer Treatment Market

18. France Solid Tumor Cancer Treatment Market

19. Italy Solid Tumor Cancer Treatment Market

20. Spain Solid Tumor Cancer Treatment Market

21. Eastern Europe Solid Tumor Cancer Treatment Market

22. Russia Solid Tumor Cancer Treatment Market

23. North America Solid Tumor Cancer Treatment Market

24. USA Solid Tumor Cancer Treatment Market

25. Canada Solid Tumor Cancer Treatment Market

26. South America Solid Tumor Cancer Treatment Market

27. Brazil Solid Tumor Cancer Treatment Market

28. Middle East Solid Tumor Cancer Treatment Market

29. Africa Solid Tumor Cancer Treatment Market

30. Solid Tumor Cancer Treatment Market Competitive Landscape And Company Profiles

31. Solid Tumor Cancer Treatment Market Other Major And Innovative Companies

32. Global Solid Tumor Cancer Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Solid Tumor Cancer Treatment Market

34. Recent Developments In The Solid Tumor Cancer Treatment Market

35. Solid Tumor Cancer Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기